Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

For any one with a straining waistband, the next step was once a given: heading to the local church hall for an evening of ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Novo Nordisk ) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...